Supplementary Files
Keywords
inflation
topical glucocorticosteroids
price regulation
offset contract
Categories
Abstract
Introduction. Atopic dermatitis (AtD) is a chronic inflammatory skin disease that reduces the quality of life of patients. Topical glucocorticosteroids are the first line of pharmacotherapy. The pharmaceutical market is constantly changing under the influence of macroeconomic factors, one of which is the inflation rate.
The aim of the study was to evaluate the dynamics of retail prices in the segment of medicines of the glucocorticosteroids group used for the pharmacotherapy of AtD in the period 2022–2025 in the Sverdlovsk Region.
Materials and methods. The empirical database was the analytics of the marketing agency DSM Group on the movement of drugs in the territory of the Sverdlovsk Region. An economic study of the dynamics of retail prices was conducted using calculations of the Fisher index for the period under study. The following methods were used in the course of the study: statistical and economic.
Results. In a comprehensive study of price dynamics, it was found that the Fischer index differed for international nonproprietary names included in the list of vital and essential drugs (VED) and those not included in this list.
Conclusion. The data obtained can be useful for assessing the affordability of medicines for patients with AtD, as well as for forming a range of pharmacy organizations in the territory of the Sverdlovsk Region. One of the possible tools for increasing affordability may be: the formation of a methodological framework for pharmaceutical counseling of patients with AtD in retail organizations; reduction of wholesale and retail allowances by wholesale and retail organizations; conclusion of regional offset contracts with Ural pharmaceutical manufacturing plants.
For citation: Tsekhmister RA, Petrov AL, Andrianova GN. Assessment of price dynamics for topical glucocorticosteroids in atopic dermatitis pharmacotherapy in Sverdlovsk Region. USMU Medical Bulletin. 2026;11(2):e00218. (In Russ.). DOI: https://doi.org/10.52420/usmumb.11.2.e00218. EDN: https://elibrary.ru/AFBGBU.
Funding. The work was performed without external funding.
Conflict of interest. Alexey L. Petrov, Galina N. Andrianova are the editorial board members of USMU Medical Bulletin; they did not participate in reviewing the material, as well as in making a decision on its publication. Roman A. Tsekhmister declares that there is no conflict of interest.
Ethics statement. No ethical review was conducted. The study involved examining the economic characteristics of the pharmaceutical market without patient participation.
References
Laughter MR, Maymone MBC, Mashayekhi S, Arents BWM, Karimkhani C, Langan SM, et al. The global burden of atopic dermatitis: Lessons from the Global Burden of Disease Study 1990–2017. British Journal of Dermatology. 2021;184(2):304–309. DOI: https://doi.org/10.1111/bjd.19580.
Odhiambo JA, Williams HC, Clayton TO, Robertson CF, Asher MI; ISAAC Phase Three Study Group. Lobal variations in prevalence of eczema symptoms in children from ISAAC Phase Three. Journal of Allergy and Clinical Immunology. 2009;124(6):1251–1258.e23. DOI: https://doi.org/10.1016/j.jaci.2009.10.009.
Deckers IA, McLean S, Linssen S, Mommers M, van Schayck CP, Sheikh A. Investigating international time trends in the incidence and prevalence of atopic eczema 1990–2010: A systematic review of epidemiological studies. PLoS One. 2012;7(7):e39803. DOI: https://doi.org/10.1371/journal.pone.0039803.
Choragudi S, Yosipovitch G. Trends in the prevalence of eczema among US children by age, sex, race, and ethnicity from 1997 to 2018. JAMA Dermatology. 2023;159(4):454–456. DOI: https://doi.org/10.1001/jamadermatol.2022.6647.
Fasseeh AN, Elezbawy B, Korra N, Tannira M, Dalle H, Aderian S, et al. Burden of atopic dermatitis in adults and adolescents: A systematic literature review. Dermatology and Therapy. 2022;12:2653–2668. DOI: https://doi.org/10.1007/s13555-022-00819-6.
Brunner PM, Leung DYM, Guttman-Yassky E. Immunologic, microbial, and epithelial interactions in atopic dermatitis. Annals of Allergy, Asthma & Immunology. 2018;120(1):34–41. DOI: https://doi.org/10.1016/j.anai.2017.09.055.
Lowe AJ, Leung DYM, Tang MLK, Su JC, Allen KJ. The skin as a target for prevention of the atopic march. Annals of Allergy, Asthma & Immunology. 2018;120(2):145–151. DOI: https://doi.org/10.1016/j.anai.2017.11.023.
Kim BE, Leung DY. Epidermal barrier in atopic dermatitis. Allergy, Asthma & Immunology Research. 2012;4(1):12–16. DOI: https://doi.org/10.4168/aair.2012.4.1.12.
Eichenfield LF, Tom WL, Chamlin SL, Feldman SR, Hanifin JM, Simpson EL, et al. Guidelines of care for the management of atopic dermatitis: Section 1. Diagnosis and assessment of atopic dermatitis. Journal of the American Academy of Dermatology. 2014;70(2):338–351. DOI: https://doi.org/10.1016/j.jaad.2013.10.010.
Proudfoot LE, Powell AM, Ayis S, Barbarot S, Baselga Torres E, Deleuran M, et al. The European treatment of severe atopic eczema in children taskforce (TREAT) survey. British Journal of Dermatology. 2013;169(4):901–909. DOI: https://doi.org/10.1111/bjd.12505.
Garnacho-Saucedo G, Salido-Vallejo R, Moreno-Giménez JC. Atopic dermatitis: Update and proposed management algorithm. Actas Dermo-Sifiliográficas. 2013;104(1):4–16. (In Eng., Span.). DOI: https://doi.org/10.1016/j.ad.2011.12.008.
Schneider L, Tilles S, Lio P, Boguniewicz M, Beck L, LeBovidge J, et al. Atopic dermatitis: A practice parameter update 2012. Journal of Allergy and Clinical Immunology. 2013;131(2):295–299.e27. DOI: https://doi.org/10.1016/j.jaci.2012.12.672.
Maroti M, Ulff E, Wijma B. Quality of life before and 6 weeks after treatment in a dermatological outpatient treatment unit. Journal of the European Academy of Dermatology and Venereology. 2006;20(9):1081–1085. DOI: https://doi.org/10.1111/j.1468-3083.2006.01704.x.
Ливанский СМ, Утёмова АС, Денисова МН. Инфляционные процессы на фармрынке: прогноз развития. Ремедиум. 2019;(3):48–52 / Livansky SM, Utyomova AS, Denisova MN. Inflationary processes in the pharmaceutical market: Development forecasting. Remedium. 2019;(3):48–52. (In Russ.). EDN: https://elibrary.ru/EOFZAW.
Костин КБ, Шанава ЛА. Ключевые тенденции развития российского фармацевтического рынка в условиях неопределенности. Экономика, предпринимательство и право. 2022;12(5):1639–1658 / Kostin KB, Shanava LA. Key trends in the development of the Russian pharmaceutical market amidst uncertainty. Journal of Economics, Entrepreneurship and Law. 2022;12(5):1639–1658. (In Russ.). DOI: https://doi.org/10.18334/epp.12.5.114635.
Графова ТО, Яковенко ВА, Кононов АН. Импортозамещение и санкционная перестройка отечественной фарминдустрии. Экономические науки. 2023;229(12):485–492 / Grafova TO, Yakovenko VA, Kononov AN. Import substitution and sanctions restructuring of the domestic pharmaceutical industry. Economic Sciences. 2023;229(12):485–492. (In Russ.). DOI: https://doi.org/10.14451/1.229.485.
Овод АИ. Изменение цен на лекарственные препараты в России в условиях кризиса. Региональный вестник. 2020;(9):94–96 / Ovod AI. Changes in prices for medicines in Russia during the crisis. Regional Bulletin. 2020;(9):94–96. (In Russ.). EDN: https://elibrary.ru/ENTVNE.
Петров АЛ, Шарафиева ЭР, Нужина МП, Гаврилов АС, Андрианова ГН. Анализ ценообразования на лекарственные препараты в Уральском Федеральном округе. Вестник современной клинической медицины. 2023;16(5):92–96 / Petrov AL, Sharafieva ER, Nuzhina MP, Andrianova GN. Analysis of pricing for drugs manufactured in the Ural Federal District. The Bulletin of Contemporary Clinical Medicine. 2023;16(5):92–96. (In Russ.). DOI: https://doi.org/10.20969/VSKM.2023.16(5).92-96.
Джупаров АС, Джупарова ИА. Анализ лекарственного обеспечения населения сельских поселений Новосибирской области. Journal of Siberian Medical Sciences. 2020;(4):74–81 / Dzhuparov AS, Dzhuparova IA. Analysis of Novosibirsk Region rural settlements population drug provision. Journal of Siberian Medical Sciences. 2020;(4):74–81. (In Russ.). DOI: https://doi.org/10.31549/2542-1174-2020-4-74-81.
Нигматуллина ЮУ, Ростова НБ. Обоснование методических подходов к оптимизации лекарственного обеспечения пациентов с раком предстательной железы. Медико-фармацевтический журнал «Пульс». 2023;25(5):75–81 / Nigmatullina YU, Rostova NB. Substantiation of methodological approaches to optimizing drug provision for patients with prostate cancer. Medical & Pharmaceutical Journal “Pulse”. 2023;25(5):75–81. (In Russ.). DOI: https://doi.org/10.26787/nydha-2686-6838-2023-25-5-75-81.
Ягудина РИ, Гаврилина НИ. Использование метода min-max в оценке эффективности здравоохранения и лекарственного обеспечения населения. Ремедиум. 2022;26(2):139–142 / Yagudina RI, Gavrilina NI. Using the min-max method in assessing the effectiveness of healthcare and drug provision of the population. Remedium. 2022;26(2):139–142. (In Russ.). DOI: https://doi.org/10.32687/1561-5936-2022-26-2-139-142.
Петров АГ, Семенихин ВА, Глембоцкая ГТ, Хорошилова ОВ. Актуальность фармакоэкономической оценки фармакотерапии полинейропатий верхних и нижних конечностей работников угольной отрасли на стационарном уровне. Фармакоэкономика: теория и практика. 2020;8(1):16–19 / Petrov AG, Semenikhin VA, Glembotskaya GT, Khoroshilova OV. Relevance of the pharmacoeconomic evaluation of the pharmacotherapy of polyneuropathies of upper and lower limbs of workers of the coal industry at the stationary level. Pharmacoeconomics: Theory and Practice. 2020;8(1):16–19. (In Russ.). DOI: https://doi.org/10.30809/phe.1.2020.3.
Копытин ДА. Государственное регулирование цен на лекарственные препараты: поиск баланса. Ремедиум. 2018;(1–2):8–14 / Kopytin DA. State regulation of prices on medicines: Search for balance. Remedium. 2018;(1–2):8–14. (In Russ.). EDN: https://elibrary.ru/YTCESC.
Орлов АС, Иванова МС, Федорина ЕВ. Факторы ценообразования на фармацевтическом рынке. В: Инновации в здоровье нации. Санкт-Петербург: Изд-во СПХФУ; 2019. С. 321–325 / Orlov AS, Ivanova MS, Fedorina EV. Pricing factors in the pharmaceutical market. In: Innovations in the Health of the Nation. Saint Petersburg: Saint Petersburg State Chemical and Pharmaceutical University Publishing House; 2019. P. 321–325. (In Russ.). EDN: https://elibrary.ru/PDMIDU.
Сура МВ. Ценовое регулирование на лекарственные препараты в Российской Федерации: текущая ситуация и возможные пути реформирования. Проблемы стандартизации в здравоохранении. 2015;(1–2):20–27 / Sura MV. Price regulation on drugs in the Russian Federation: Current situation and possible ways of reform. Health Care Standardization Problems. 2015;(1–2):20–27. (In Russ.). EDN: https://elibrary.ru/RKTXKD.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License
Copyright © 2026 Tsekhmister R. A., Petrov A. L., Andrianova G. N.